ADDRESSING A MANUFACTURING BOTTLENECK IN CAR-T THERAPY: SCALABLE PRODUCTION OF TRANSFECTION-GRADE PLASMID DNA FOR CAR-T VECTOR MANUFACTURING
The rapid advancing of cell and gene therapy has increased the demand for plasmid DNA used in viral vector manufacturing. The production of transfection-grade plasmid DNA remains a critical bottleneck, particularly for academic and emerging manufacturing facilities, due to the high cost and limited scalability of exist...